Madrigal Pharmaceuticals Inc Cash Flow Conversion Efficiency
Madrigal Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has a cash flow conversion efficiency ratio of -0.221x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-133.46 Million) by net assets ($602.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Madrigal Pharmaceuticals Inc (2003–2025)
Cash flow conversion efficiency of Madrigal Pharmaceuticals Inc from 2003 to 2025. This chart illustrates how Madrigal Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MDGL stock price for real-time trading data and today's change.
Madrigal Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Madrigal Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Madrigal Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market value of Madrigal Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Penske Automotive Group Inc
NYSE:PAG
|
0.038x |
|
QXO, Inc.
NYSE:QXO
|
0.007x |
|
GAIL (India) Limited
NSE:GAIL
|
0.065x |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
0.030x |
|
Azrieli Group Ltd
TA:AZRG
|
0.022x |
|
Baxter International Inc
NYSE:BAX
|
0.046x |
|
Semtech Corporation
NASDAQ:SMTC
|
0.092x |
|
ZTO EXPRESS (CAYMAN)
F:ZTOB
|
N/A |
Annual Cash Flow Conversion Efficiency for Madrigal Pharmaceuticals Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Madrigal Pharmaceuticals Inc from 2003 to 2025. Review cash generation quality of Madrigal Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $602.69 Million | $-189.55 Million | -0.315x | +47.92% |
| 2024-12-31 | $754.38 Million | $-455.57 Million | -0.604x | +24.50% |
| 2023-12-31 | $405.33 Million | $-324.23 Million | -0.800x | +29.78% |
| 2022-12-31 | $197.39 Million | $-224.86 Million | -1.139x | -21.47% |
| 2021-12-31 | $196.11 Million | $-183.92 Million | -0.938x | -42.84% |
| 2020-12-31 | $239.97 Million | $-157.56 Million | -0.657x | -557.10% |
| 2019-12-31 | $416.56 Million | $-41.62 Million | -0.100x | -86.86% |
| 2018-12-31 | $476.98 Million | $-25.51 Million | -0.053x | +56.33% |
| 2017-12-31 | $182.26 Million | $-22.32 Million | -0.122x | +74.68% |
| 2016-12-31 | $36.41 Million | $-17.61 Million | -0.484x | +65.88% |
| 2015-12-31 | $50.41 Million | $-71.44 Million | -1.417x | -16.97% |
| 2014-12-31 | $65.14 Million | $-78.92 Million | -1.212x | +23.16% |
| 2013-12-31 | $49.09 Million | $-77.41 Million | -1.577x | -118.66% |
| 2012-12-31 | $75.07 Million | $-54.13 Million | -0.721x | +77.47% |
| 2011-12-31 | $14.77 Million | $-47.30 Million | -3.202x | -96.78% |
| 2010-12-31 | $23.48 Million | $-38.20 Million | -1.627x | -51.17% |
| 2009-12-31 | $24.91 Million | $-26.81 Million | -1.076x | -266.77% |
| 2008-12-31 | $-58.79 Million | $-37.94 Million | 0.645x | -40.98% |
| 2007-12-31 | $24.90 Million | $27.22 Million | 1.093x | -96.39% |
| 2006-12-31 | $-1.75 Million | $-52.98 Million | 30.329x | +2671.96% |
| 2005-12-31 | $52.48 Million | $-61.88 Million | -1.179x | -311.59% |
| 2004-12-31 | $117.96 Million | $-33.80 Million | -0.287x | +6.70% |
| 2003-12-31 | $76.89 Million | $-23.61 Million | -0.307x | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.